Analyst Activity – HC Wainwright Raises Its Price Target On NASDAQ:GALT – Galectin Therapeutics (NASDAQ:GALT) to

ME Staff
-
0

Analyst Ratings For NASDAQ:GALT – Galectin Therapeutics (NASDAQ:GALT)

Today, HC Wainwright raised its price target on NASDAQ:GALT – Galectin Therapeutics (NASDAQ:GALT) to per share.

Some recent analyst ratings include

  • 10/6/2017-Seaport Global Securities Reiterated Rating of Buy.
  • 4/3/2017-FBR & Co Reiterated Rating of Market Perform.

Recent Insider Trading Activity For NASDAQ:GALT – Galectin Therapeutics (NASDAQ:GALT)
NASDAQ:GALT – Galectin Therapeutics (NASDAQ:GALT) has insider ownership of 45.20% and institutional ownership of 9.60%.

  • On 4/16/2018 Theodore Daniel Zucconi, Director, sold 4,000 with an average share price of $3.58 per share and the total transaction amounting to $14,320.00.
  • On 4/4/2018 Jack W Callicutt, CFO, sold 3,349 with an average share price of $5.00 per share and the total transaction amounting to $16,745.00.
  • On 2/1/2018 Kevin D Freeman, Director, bought 2,000 with an average share price of $4.10 per share and the total transaction amounting to $8,200.00.
  • On 1/26/2018 Fund L.P. 10X, Major Shareholder, sold 244,444 with an average share price of $5.43 per share and the total transaction amounting to $1,327,330.92.
  • On 1/25/2018 James C Czirr, Director, sold 205,144 with an average share price of $5.45 per share and the total transaction amounting to $1,118,034.80.
  • On 12/8/2017 Marc Rubin, Director, bought 7,000 with an average share price of $1.85 per share and the total transaction amounting to $12,950.00.
  • On 5/23/2017 Theodore Daniel Zucconi, Director, bought 1,000 with an average share price of $2.27 per share and the total transaction amounting to $2,270.00.

Recent Trading Activity for NASDAQ:GALT – Galectin Therapeutics (NASDAQ:GALT)
Shares of NASDAQ:GALT – Galectin Therapeutics closed the previous trading session at 4.26 up +0.26 6.50% with 4.170000076293945 shares trading hands.